KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Liabilities (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Total Liabilities for 9 consecutive years, with $633.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 34.46% year-over-year to $633.3 million, compared with a TTM value of $633.3 million through Dec 2025, down 34.46%, and an annual FY2025 reading of $633.3 million, down 34.46% over the prior year.
  • Total Liabilities was $633.3 million for Q4 2025 at Biocryst Pharmaceuticals, down from $834.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $972.5 million in Q4 2023 and bottomed at $421.6 million in Q2 2025.
  • Average Total Liabilities over 3 years is $858.5 million, with a median of $932.9 million recorded in 2023.
  • The sharpest move saw Total Liabilities increased 12.65% in 2024, then plummeted 55.53% in 2025.
  • Year by year, Total Liabilities stood at $972.5 million in 2023, then fell by 0.63% to $966.4 million in 2024, then plummeted by 34.46% to $633.3 million in 2025.
  • Business Quant data shows Total Liabilities for BCRX at $633.3 million in Q4 2025, $834.3 million in Q3 2025, and $421.6 million in Q2 2025.